CSU 134/2011: A RESEARCH AGENDA FOR MALARIA ERADICATION: VACCINES
| Saturday, 16th of April 2011 |
 |
 |
Summary Points
Full text is at http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000398
Vaccines for malaria eradication need to have an impact on transmission rather than focusing on mortality and morbidity reduction alone
Vaccines that interrupt malaria transmission (VIMT) may target many stages of the parasite’s life cycle, not just the sexual and mosquito stages as in classical blocking vaccines and multiple plasmodium species, in particular Plasmodium vivax
Novel vaccine delivery approaches and adjuvants need to be developed
Other priority areas for research and development include the development of tools to measure transmission rates and the development of robust assays of functional immune responses in individuals, which could inform vaccine development
A better understanding of the dynamics between the multiplication of parasites, gametocytogenesis, and malaria transmission rates in populations is also needed
| Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
| Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
| Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
| Immunization Agenda 2030
Tuesday, 11th of February 2020 |
 |
40951593 |
| www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |